Justin Waite on X: "Coverage in the Telegraph about Polarean #POLX. As I mentioned in my weekend video. It's the addition of a new manufacturer that seems to be the issue. Polarean are also confident the issues can be addressed. https://t.co ...
Justin Waite on X: ""Upon FDA approval (90% probability), we value Polarean #POLX at 135p per share on a risk-adjusted NPV basis, which implies c.50% upside to the current share price, hence
Polarean Imaging says FDA rejects new drug application, shares slump | Reuters